Among the patients harboring NRAS variants, two carrying the UBA1 variants R182H (MDS) and E597A (CML + secondary myelofibrosis [MF] after essential thrombocythemia [ET] treatment) were known with a history of prior treatment against CLL (rituximab-fludarabine-cyclophosphamide; R-FC) and CML (imatinib), respectively. Here, UBA1 is linked to myelodysplastic syndrome.